Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.

Sodium-glucose transporter 2 (SGLT2) inhibitors are safe and well-tolerated in people with heart failure (HF) related to adult congenital heart disease (ACHD) and associated with reduced ...

SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...

BOSTON -- Sodium-glucose cotransporter-2 (SGLT2) inhibitors were linked to long-term reductions in mortality risk among patients with pulmonary arterial hypertension (PAH), according to an ...

Please provide your email address to receive an email when new articles are posted on . Adults aged 60 years or older had a similar 5-year risk for dementia with SGLT2 inhibitors as with dulaglutide.

The use of SGLT2 inhibitors was not associated with a clear increase in overall UTI risk among patients with RA and diabetes.

SGLT-2 inhibitor use, compared with DPP-4 inhibitor use, was associated with a lower incidence of epilepsy among patients with type 2 diabetes. The use of sodium-glucose cotransporter 2 (SGLT-2) ...

SGLT2 inhibitors combat inflammation and slow kidney disease by elevating S-adenosylmethionine (SAM) levels, which suppress inflammatory gene activity through epigenetic modification. The benefits of ...

Please provide your email address to receive an email when new articles are posted on . Treatment with SGLT2 inhibitors was associated with decreased mortality but increased incidence of lupus ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...